Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine: Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6

Biochemical Pharmacology

Volumn 51, Issue 2, 1996, Pages 165-172

  Yumibe, Nathan ^a   Huie, Keith ^a   Chen, Kwang Jong ^a   Snow, Mark ^a   Clement, Robert P ^a   Cayen, Mitchell N ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cytochrome P450; Human; In vitro metabolism; Liver; Loratadine; Molecular modeling

Indexed keywords

ANTIHISTAMINIC AGENT; BENZYLSULFONYL FLUORIDE; CAFFEINE; CHLORZOXAZONE; COMPLEMENTARY DNA; COUMARIN; CYTOCHROME P450 ISOENZYME; DESLORATADINE; DEXTROMETHORPHAN; DRUG METABOLITE; ENZYME ANTIBODY; ENZYME INHIBITOR; ESTERASE INHIBITOR; KETOCONAZOLE; LORATADINE; MEPHENYTOIN; POLYCLONAL ANTIBODY; QUINIDINE; RADIOISOTOPE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TESTOSTERONE; TOLBUTAMIDE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DEMETHYLATION; DRUG CONFORMATION; DRUG METABOLISM; ENZYME SUBSTRATE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYDROLYSIS; HYDROXYLATION; LIVER MICROSOME METABOLISM; MOLECULAR MODEL; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIMALARIALS; BINDING SITES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; HISTAMINE H1 ANTAGONISTS; HUMANS; KETOCONAZOLE; LORATADINE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, MOLECULAR; OXIDATION-REDUCTION; PIPERIDINES; PYRIDINES; QUINIDINE; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TROLEANDOMYCIN;

EID: 0030048830     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02169-8     Document Type: Article

References (26)

1. Haria M, Fitton A and Peters DH, Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 48: 617-637, 1994.
2. Clissold SP, Sorkin EM and Goa KL, Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 37: 42-57, 1989.
3. 14C-SCH 29851 in humans. Ann Allergy 55: 393, 1985.
4. Weyer A, Czarlewski W, Carmi-Leroy A and David B, In vitro inhibition by loratadine and its active metabolite of anti-IgE induced histamine release from human basophils. J Allergy Clin Immunol 89: 222, 1992.
5. Hilbert J, Radwanski E, Weglein R, Luc V, Perentesis G, Symchowicz S and Zampaglione N, Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol 27: 694-698, 1987.
6. Beaune PH, Kremers PG, Kaminsky LS, De Graeve J, Albert A and Guengerich FP, Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes. Drug Metab Dispos 14: 437-442, 1986.
7. Mohamadi F, Richards N, Guida W, Liskamp R, Caufield C, Chang G, Hendrickson T and Still W, MacroModel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 11: 440-467, 1990.
8. 1 activity. Clin Pharmacol Ther 45: 34-40, 1989.
9. Spartan V3.0. Wavefunction, Inc., Irvine, CA 92715, 1993.
10. Seitz R, Heidtmann H, Massberg M, Immel A, Egbring R and Havemann K, Activators of coagulation in cultured human lung-tumor cells. Int Cancer 53: 514-520, 1993.
11. Guengerich FP, Peterson LA and Böcker HR, Cytochrome P-450-catalyzed hydroxylation and carboxylic acid ester cleavage of Hantzsch pyridine esters. J Biol Chem 263: 8176-8183, 1988.
12. Guengerich FP, Oxidative cleavage of carboxylic esters by cytochrome P-450. J Biol Chem 262: 8459-8462, 1987.
13. Young HD, Statistical Treatment of Experimental Data. McGraw-Hill, New York, 1962.
14. Van Tyle JH, Ketoconazole mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 4: 343-373, 1984.
15. Back DJ, Stevenson P and Tjia JF, Comparative effects of two antimycotic agents, ketoconazole and terbinafine, on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 28: 166-170, 1989.
16. Back DJ, Tjia JF and Abel SM, Azoles, allyamines and drug metabolism. Br J Dermatol 126: 14-18, 1992.
17. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G and Maurel P, Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18: 595-606, 1990.
18. Guengerich FP, Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3: 363-371, 1990.
19. Franklin MR, Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. In: Methods in Ensymology (Eds. Waterman MR and Johnson EF), Vol. 206, pp. 559-573. Academic Press, San Diego, CA, 1991.
20. Cholerton S, Daly AK and Idle JR, The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13: 434-439, 1992.
21. Watkins PB, Wrighton SA, Maurel P, Schetz EG, Mendez-Picon G, Parker GA and Guzelian PS, Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 82: 6310-6314, 1985.
22. Eberhart DC, Gemzik B, Halvorson MR and Parkinson A, Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol Pharmacol 40: 859-867, 1991.
23. Brian WR, Sari M-A, Iwasaki M, Shimada T, Kaminsky LS and Guengerich FP, Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29: 11280-11292, 1990.
24. Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV and Guengerich FP, Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 45: 2116-2122, 1985.
25. Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT and Catin T, The molecular mechanisms of two common polymorphisms of drug oxidation - Evidence for functional changes in cytochrome P-450 isozymes catalyzing bufuralol and mephenytoin oxidation. Xenobiotica 16: 449-464, 1986.
26. Koymans L, Vermeulen NP, van Acker SA, te Koppele JM, Heykants JJ, Lavrijsen K, Meuldermans W and Donné-Op den Kelder GM, A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5: 211-219, 1992.